Drugs / AD-227B
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06884085 | Jul → Aug 2025 | essential hypertension | Addpharma Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06441630 | Jul 2024 → Sep 2025 overdue | essential hypertension | Addpharma Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-227B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06441630 ↗ |
| Route | Oral | “Per Oral, 1 Tablet, Once a day for 8 weeks” NCT06441630 ↗ |